Cite
HARVARD Citation
Reck, M. et al. (n.d.). 1386PDIMpower150: Clinical safety, tolerability and immune-related adverse events in a phase III study of atezolizumab (atezo) + chemotherapy (chemo) ± bevacizumab (bev) vs chemo + bev in 1L nonsquamous NSCLC. Annals of oncology. p. . [Online].